L&T unit lands $571m GCC power project contracts
India's top engineering and construction conglomerate Larsen & Toubro (L&T) has announced that its Power Transmission & Distribution (PT&D) vertical has secured power project orders - valued in the range of Rs25 billion to Rs50 billion ($285 million to $571 million) - from its prime GCC markets of Saudi Arabia and UAE.
Confirming the significant orders, L&T said its PT&D vertical has clinched an order from Saudi Arabia for a 380kV Gas Insulated Substation (GIS). The scope also includes associated reactors and installation of hybrid GIS Bays.
In Abu Dhabi, UAE, the business has received an order for setting up a new 220/33kV grid station, along with associated jobs, said L&T in a statement.
These repeat orders from PT&D's longstanding customers underscore the vital role played by L&T towards setting up efficient grid infrastructure across geographies, and thereby facilitating faster proliferation of renewable energy generation, it stated.
In addition, the PT&D has bagged orders in India where it will be implementing 765kV and 400kV transmission line segments associated with a Renewable Energy Zone in the north Indian state of Uttar Pradesh.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Tribune
2 days ago
- Daily Tribune
New hope for patients with less common breast cancer
A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new firstline therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15–20% of all breast cancer cases. HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. 'Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for,' oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This 'smart bomb' strategy allows the drug to target cancer cells directly. 'You can bind to the cancer cell and dump all that chemo right into the cancer cells,' explained Tolaney. 'Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much.' Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a 'second-line' option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 percent risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44% compared to standard care. Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5% in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission. 'This represents a new firstline standard treatment option for HER2-positive metastatic breast cancer,' said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study.
Daily Tribune
3 days ago
- Daily Tribune
Kohli's IPL dream faces Punjab challenge
Punjab Kings stand in the way of Virat Kohli's dream of finally winning the Indian Premier League in today's final at the world's biggest cricket stadium. No matter which team prevails at the 132,000-capacity venue in Ahmedabad it will be a first -- neither Punjab nor Kohli's Royal Challengers Bengaluru have won the IPL since it launched in 2008. Punjab booked their place in the decider with a five-wicket victory over five-time champions Mumbai Indians on Sunday. Shreyas Iyer played a captain's knock with an unbeaten 87. Kohli and Bengaluru will have a psychological edge after thrashing Punjab by eight wickets at the start of the playoffs last week. It is the fourth time that Kohli and his team have reached the final of cricket's richest tournament, but they have never been able to take that last step. The vast majority in attendance will be cheering on Kohli, the 36-year-old superstar batsman and icon to Indian cricket fans. Kohli, who last month retired from Test cricket alongside Rohit Sharma, has again been Bengaluru's go-to batsman with 614 runs, including eight half-centuries, in 14 innings this season. He has made no attempt to hide his desperation to win the IPL at the 18th attempt and add it to a long list of accolades that includes two World Cup crowns. He has talked about his 'heartbreak' of f ailing to win the IPL, and celebrated last week's win against Punjab saying: 'One more to go.' Punjab's fast bowling coach James Hopes said yesterday his team will be ' recovering and getting mentally prepared' for what he anticipates will be a 'pretty big crowd, and a pretty big proKohli crowd as well'. Sensational Iyer As well as Kohli, Bengaluru boast the significant threat of Australian fast bowler Josh Hazlewood. The 34-year-old returned following a shoulder injury and a stint back home to put in a manof-the-match performance i n the win over Punjab in the qualifier. He returned figures of 3-21 to help bundle Punjab out for 101. Hazlewood spearheads a seam-bowling attack alongside Bhuvneshwar Kumar and left-armer Yash Dayal. Punjab, coached by Australia great Ricky Ponting , recovered from defeat to win the rain-delayed second qualifier in Ahmedabad. Skipper Iyer, who cost $3.17 million in November's auction, is narrowly behind Kohli in the batting charts with 603 runs from 16 innings. His latest chase masterclass off 41 balls, laced with five fours and eight sixes, is a reminder that he is lethal on his day. 'I love such big occasions,' Iyer said after the win over Mumbai. 'I always say to myself and my colleagues that the bigger the occasion, the calmer you are, and you'll get the best results.' Former Australia medium-pace bowler Hopes said that Iyer 'doesn't get flustered very easily'. 'He knows what he has to do and he's prepared to take that risk,' said Hopes. 'He is a sensational captain and a sensational player,' he added. Punjab openers Priyansh Arya and Prabhsimran Singh are in good form, and they have another potential match-winner in Australia's Josh Inglis. All-rounders Marcus Stoinis from Australia and Afghanistan's Azmatullah Omarzai can also threaten Kohli's long-awaited dream.
Daily Tribune
4 days ago
- Daily Tribune
Indian airline IndiGo orders 30 Airbus A350 widebody planes
India Indian airline IndiGo said yesterday it had signed an order for 30 more Airbus A350-900s, bringing its shopping list for the widebody aircraft from the European aircraft manufacturer to 60. 'We are placing a firm order for 30 Airbus A350- 900s,' said Pieter Elbers, the CEO of IndiGo, which was founded in 2006 and is behind the largest contract by volume in the history of civil aviation -- 500 Airbus single-aisle aircraft by 2023. The low-cost carrier, India's biggest by market share, is positioning itself as a significant player in the long-haul market.'This strategic move will enable IndiGo to spread its wings further and expand its long-haul international network,' the company said. Benoit de Saint-Exupery, Airbus commercial aircraft vice-president of sales, hailed 'IndiGo's incredible rise'. 'You have democratised flying in India, and now you want to expand internationally,' he said. The A350 planes, with ranges of up to 15,000 kilometres (9,300 miles), will allow it to expand its network further. O ve ra l l , I n d i G o h a s placed orders for around 1,000 aircraft from the A320 family, Airbus's most successful model and rival of the Boeing 737 MAX, which has endured multiple setbacks.
